52
Participants
Start Date
July 3, 2024
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2028
Durvalumab / tremelimumab
"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
NOT_YET_RECRUITING
Duke Cancer Institute, Durham
RECRUITING
Baylor St Lukes, Houston
Duke Cancer Institute
OTHER
Baylor College of Medicine
OTHER